How does PEPITEM differ from conventional immunosuppressants?

Most immunosuppressants broadly dampen the immune system. PEPITEM selectively blocks T cell migration into inflamed tissues without affecting neutrophils, macrophages, or other immune cells. It works by restoring a natural regulatory mechanism rather than overriding the immune system, which could mean fewer side effects like increased infection risk.

Why does PEPITEM decline with age?

The adiponectin-PEPITEM pathway weakens as we age. B cells from older individuals produce less PEPITEM in response to adiponectin stimulation. This contributes to 'inflammaging' — the chronic low-grade inflammation that drives many age-related diseases. Supplementing PEPITEM in aged mice restored proper immune cell trafficking.

Is PEPITEM available as a treatment?

No. PEPITEM is in the preclinical research stage. It has not entered human clinical trials and is not commercially available. The University of Birmingham group is actively developing it, including identifying active tripeptide fragments that could be easier to manufacture and deliver.

PEPITEM

A naturally occurring immunopeptide that controls T cell migration into inflamed tissues. Discovered at the University of Birmingham, PEPITEM shows preclinical promise for inflammatory arthritis, multiple sclerosis, lupus, psoriasis, bone loss, and age-related immune decline.

EmergingLimited Data

What is PEPITEM?

PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) is a naturally occurring peptide derived from the 14-3-3 zeta delta protein, secreted by B cells in response to adiponectin signaling. Discovered by researchers at the University of Birmingham and published in Nature Medicine in 2015, PEPITEM acts as a built-in brake on inflammation — it selectively prevents T cells from crossing blood vessel walls into tissues, without affecting other immune cells. This pathway weakens with age and is impaired in autoimmune conditions like rheumatoid arthritis and type 1 diabetes, where circulating PEPITEM levels are measurably reduced. The concept of "PEPITEM replacement therapy" — supplementing what the body no longer produces enough of — is now being explored across multiple inflammatory and age-related conditions.

Why People Talk About It

Inflammatory arthritis (comparable to infliximab in animal models)

Emerging

Multiple sclerosis / autoimmune neuroinflammation

Preliminary

Bone loss and osteoporosis (anabolic + anti-resorptive)

Emerging

Age-related immune decline (inflammaging)

Preliminary

Psoriasis (topical application)

Preliminary

Lupus glomerulonephritis

Preliminary

How It Works

Your body naturally produces PEPITEM to keep inflammation in check. When adiponectin (a hormone from fat tissue) signals B cells, they release PEPITEM, which tells blood vessel walls to stop letting T cells (a type of immune cell) pass through into tissues. As you age or develop autoimmune conditions, this system breaks down — you produce less PEPITEM, and T cells flood into joints, organs, and tissues, causing chronic inflammation.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

No adverse effects reported in preclinical studiesMechanism selectively targets T cell migration, sparing other immune functions

Cautions

• No human clinical trials have been conducted
• Not commercially available
• Long-term effects of exogenous PEPITEM supplementation are unknown
• Exclusively a research compound at this stage

What We Don't Know

All data is preclinical. Whether PEPITEM replacement therapy will be safe and effective in humans is unproven. The selectivity for T cell trafficking (sparing other immune cells) is promising for safety but needs human validation. Optimal dosing, route, and duration for different conditions are undefined.

Published Research

9 studies

Engineering Peptide Modulators for T-Cell Migration by Structural Scaffold Matching.

PreclinicalPMID: 40795266

PEPITEM, its tripeptide pharmacophores and their peptidomimetic analogues regulate the inflammatory response in models of peritonitis and psoriasis.

PreclinicalPMID: 39855372

Prophylactic administration of PEPITEM in experimental autoimmune encephalomyelitis delays disease onset.

PreclinicalPMID: 39802871

Rejuvenation of leukocyte trafficking in aged mice through PEPITEM intervention.

PreclinicalPMID: 39025913

Therapeutic avenues in bone repair: Harnessing an anabolic osteopeptide, PEPITEM, to boost bone growth and prevent bone loss.

PreclinicalPMID: 38776873

PEPITEM Treatment Ameliorates EAE in Mice by Reducing CNS Inflammation, Leukocyte Infiltration, Demyelination, and Proinflammatory Cytokine Production.

PreclinicalPMID: 38139072

PEPITEM/Cadherin 15 Axis Inhibits T Lymphocyte Infiltration and Glomerulonephritis in a Mouse Model of Systemic Lupus Erythematosus.

PreclinicalPMID: 32169847

Homeostatic regulation of T cell trafficking by a B cell-derived peptide is impaired in autoimmune and chronic inflammatory disease.

PreclinicalPMID: 25894827

PEPITEM 'replacement therapy' shows potential for early-stage inflammatory arthritis.

Research Summary

Mechanism of Action

PEPITEM is proteolytically derived from the 14-3-3 zeta delta protein and released by B cells in response to adiponectin receptor activation. It binds cadherin-15 (CDH15) on vascular endothelial cells, activating sphingosine kinase 1 to synthesize sphingosine-1-phosphate (S1P). S1P is exported via the Spns2 transporter to the extracellular space, where it engages S1P receptor 1 (S1PR1) on adherent T cells. This signaling reduces T cell LFA-1 and endothelial ICAM-1 expression, selectively blocking T cell trans-endothelial migration without affecting neutrophil or monocyte recruitment. In bone tissue, PEPITEM acts through a separate NCAM-1-dependent pathway: it directly stimulates osteoblast maturation and new bone formation while triggering osteoprotegerin release that sequesters RANKL, limiting osteoclast-mediated bone resorption. The pathway is impaired in aging (reduced B cell PEPITEM secretion), rheumatoid arthritis, and type 1 diabetes, with measurably lower circulating PEPITEM in patient serum compared to healthy controls.

Evidence Snapshot

Overall Confidence45%

Human Clinical Evidence

None — no human clinical trials have been conducted. However, ex vivo studies using human blood samples from patients with rheumatoid arthritis, type 1 diabetes, and elderly donors demonstrate that the PEPITEM pathway is impaired and that exogenous PEPITEM restores T cell trafficking control in patient-derived samples (Nature Medicine, 2015).

Animal / Preclinical

Strong and expanding. Inflammatory arthritis: joint swelling reduction comparable to infliximab, with reduced cartilage damage, bone erosion, and inflammatory markers (Arthritis & Rheumatology, 2026). Multiple sclerosis (EAE model): delayed disease onset, reduced CNS inflammation and demyelination (2023, 2024). Lupus: inhibited T cell infiltration and glomerulonephritis (2020). Bone: halted osteoporosis-induced bone loss and stimulated new bone formation (Cell Reports Medicine, 2024). Aging: restored immune cell trafficking in aged mice (NPJ Aging, 2024). Psoriasis: topical application reduced disease severity (2025). Peritonitis: reduced T cell, neutrophil, and macrophage infiltration (2025).

Mechanistic Rationale

Strong. Published in Nature Medicine with a clearly characterized signaling cascade: adiponectin → B cell PEPITEM release → CDH15 binding → S1P synthesis → S1PR1 activation → LFA-1/ICAM-1 reduction → selective T cell migration block. The separate NCAM-1 bone pathway is also well-characterized. The mechanism explains both the disease association (impaired in RA, T1D, aging) and the therapeutic rationale (replacement therapy).

Forms & Administration

PEPITEM has been administered via injection (intraperitoneal, subcutaneous) and topically in preclinical models. Active tripeptide pharmacophores and peptidomimetic analogues are being developed for improved delivery. It is not available for clinical use. All research peptides should only be used in the context of approved research protocols.

Use Cases & Evidence Levels

Inflammatory arthritis (comparable to infliximab in animal models)

Emerging50%

Multiple sclerosis / autoimmune neuroinflammation

Preliminary30%

Bone loss and osteoporosis (anabolic + anti-resorptive)

Emerging50%

Age-related immune decline (inflammaging)

Preliminary30%

Psoriasis (topical application)

Preliminary30%

Lupus glomerulonephritis

Preliminary30%

Safety Profile

Safety Information

Common Side Effects

No adverse effects reported in preclinical studiesMechanism selectively targets T cell migration, sparing other immune functions

Cautions

• No human clinical trials have been conducted
• Not commercially available
• Long-term effects of exogenous PEPITEM supplementation are unknown
• Exclusively a research compound at this stage

What We Don't Know

Published Research

9 studies

Engineering Peptide Modulators for T-Cell Migration by Structural Scaffold Matching.

PreclinicalPMID: 40795266

PEPITEM, its tripeptide pharmacophores and their peptidomimetic analogues regulate the inflammatory response in models of peritonitis and psoriasis.

PreclinicalPMID: 39855372

Prophylactic administration of PEPITEM in experimental autoimmune encephalomyelitis delays disease onset.

PreclinicalPMID: 39802871

Rejuvenation of leukocyte trafficking in aged mice through PEPITEM intervention.

PreclinicalPMID: 39025913

Therapeutic avenues in bone repair: Harnessing an anabolic osteopeptide, PEPITEM, to boost bone growth and prevent bone loss.

PreclinicalPMID: 38776873

PEPITEM Treatment Ameliorates EAE in Mice by Reducing CNS Inflammation, Leukocyte Infiltration, Demyelination, and Proinflammatory Cytokine Production.

PreclinicalPMID: 38139072

PEPITEM/Cadherin 15 Axis Inhibits T Lymphocyte Infiltration and Glomerulonephritis in a Mouse Model of Systemic Lupus Erythematosus.

PreclinicalPMID: 32169847

Homeostatic regulation of T cell trafficking by a B cell-derived peptide is impaired in autoimmune and chronic inflammatory disease.

PreclinicalPMID: 25894827

PEPITEM 'replacement therapy' shows potential for early-stage inflammatory arthritis.

Research Summary

Related Peptides

LL-37

Emerging

A naturally occurring antimicrobial peptide that plays a key role in innate immune defense.

KPV

EmergingBeginner

A tripeptide fragment of alpha-MSH with potent anti-inflammatory properties, studied for inflammatory bowel disease and skin conditions.

Thymosin Alpha-1

Strong

A thymic peptide approved in multiple countries for immune modulation, particularly in hepatitis and as a vaccine adjuvant.

BPC-157

EmergingBeginner

A synthetic peptide derived from a protective protein found in gastric juice, widely discussed for tissue repair and recovery.

Larazotide

ModerateBeginner

A synthetic peptide that regulates intestinal tight junctions, in clinical trials for celiac disease and studied for leaky gut conditions.

Quick Facts

Class: Immunoregulatory Peptide
Evidence: Emerging
Safety: Limited Data
Updated: Apr 2026
Citations: 9PubMed

Also known as

Peptide Inhibitor of Trans-Endothelial Migration14-3-3 Zeta Delta-Derived Peptide

Evidence Score

Overall Confidence45%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.